Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma - Iida - 2018 - Cancer Science - Wiley Online Library
Bortezomib-thalidomide-dexamethasone is superior to thalidomide- dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation. - ppt download
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial - The Lancet Haematology
Current Oncology | Free Full-Text | Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients
D-VTd, daratumumab, bortezomib, thalidomide, dexamethasone; D-VRd,... | Download Scientific Diagram
Benefits of additional cycles of bortezomib/thalidomide/dexamethason
British Journal of Haematology | Wiley Online Library
Multiple Myeloma in: Journal of the National Comprehensive Cancer Network Volume 9 Issue 10 (2011)
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study - ScienceDirect
VTd Vs Vd Vs VMP - Multiple Myeloma Clinical Trials
Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL) : a randomised, multi-centre phase II trial - WRAP: Warwick Research Archive Portal
![PDF] Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/96c7781d6fa4259ed9eba04dca6683938899d098/3-Table2-1.png "PDF] Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. | Semantic Scholar")
PDF] Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. | Semantic Scholar
Bortezomib, thalidomide and dexamethasone protocol (VTD). | Download Scientific Diagram
![PDF] Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/96c7781d6fa4259ed9eba04dca6683938899d098/3-Table4-1.png "PDF] Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. | Semantic Scholar")
PDF] Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. | Semantic Scholar
Short‑course bortezomib‑based retreatment for patients with multiple myeloma who had received bortezomib‑thalidomide‑dexamethasone (VTD) as an initial therapy: A single‑center case series
Dialysis Independence Following Combination Daratumumab, Thalidomide, Bortezomib, Cyclophosphamide, and Dexamethasone in Multiple Myeloma With Severe Renal Failure - Clinical Lymphoma, Myeloma and Leukemia
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study - The ...
Novel Three-Drug Combinations of Bortezomib, Thalidomide, Dexamethasone and Lenalidomide for Newly Diagnosed Multiple Myeloma (MM) | Research To Practice
Darzalex ®▽ (daratumumab) approved for reimbursement in Ireland in Combination with Bortezomib, Thalidomide and Dexamethasone (VTd) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible - Hospital Professional News
Impact of Modified Thalidomide Dosing in Bortezomib/Thalidomide/ Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible: A Matching-Adjusted Indirect Comparison - ScienceDirect
Newly Diagnosed: D + VTD Treatment | DARZALEX® IV (daratumumab)
![PDF] Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5d09b7e127f739fa3c3fa353bd310892f788ca9a/5-Table1-1.png "PDF] Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study | Semantic Scholar")